{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:16Z","timestamp":1794002116447,"version":"4.8.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["B21024"],"award-info":[{"award-number":["B21024"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["20161313"],"award-info":[{"award-number":["20161313"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2023LC03"],"award-info":[{"award-number":["YG2023LC03"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local University in Shanghai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173076"],"award-info":[{"award-number":["82173076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373351"],"award-info":[{"award-number":["82373351"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172596"],"award-info":[{"award-number":["82172596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anti-Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA0916700"],"award-info":[{"award-number":["2024YFA0916700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020737","name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","doi-asserted-by":"publisher","award":["RJTJ24-MS-001"],"award-info":[{"award-number":["RJTJ24-MS-001"]}],"id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020737","name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","doi-asserted-by":"publisher","award":["RJZZ18-020"],"award-info":[{"award-number":["RJZZ18-020"]}],"id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020737","name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","doi-asserted-by":"publisher","award":["RJPY-LX-001"],"award-info":[{"award-number":["RJPY-LX-001"]}],"id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.neo.2025.101216","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:18:57Z","timestamp":1754497137000},"page":"101216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study"],"prefix":"10.1016","volume":"68","author":[{"given":"Lu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haige","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2025.101216_bib0001","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.molmed.2024.04.004","article-title":"Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer","volume":"30","author":"Ben-David","year":"2024","journal-title":"Trends. Mol. Med."},{"key":"10.1016\/j.neo.2025.101216_bib0002","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-020-0880-5","article-title":"Trimodality therapy for muscle-invasive bladder cancer: recent advances and unanswered questions","volume":"22","author":"Jiang","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.neo.2025.101216_bib0004","article-title":"Bladder preservation strategies in muscle-invasive Bladder Cancer: recommendations from the International Bladder Cancer Group","author":"Gupta","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0006","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies","author":"Matsukawa","year":"2024","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.neo.2025.101216_bib0007","first-page":"41","article-title":"Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): a multicenter phase 2 trial","author":"Economides","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0008","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of Pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","volume":"9","author":"Tissot","year":"2023","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.neo.2025.101216_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102085","article-title":"Disitamab Vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder cancer: a real-world study","volume":"22","author":"Wang","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.neo.2025.101216_bib0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with Human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0011","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1186\/s12885-025-14234-5","article-title":"Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial","volume":"25","author":"Lan","year":"2025","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.neo.2025.101216_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2025.101216_bib0013","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabieres","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2025.101216_bib0014","article-title":"The Liquid Biopsy Consortium: challenges and opportunities for early cancer detection and monitoring","volume":"4","author":"Batool","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.neo.2025.101216_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.05.014","article-title":"Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma","author":"Nordentoft","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0016","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0017","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.6166","article-title":"Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial","volume":"261","author":"Zang","year":"2023","journal-title":"J. Pathol."},{"key":"10.1016\/j.neo.2025.101216_bib0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neo.2025.101216_bib0019","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0020","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-23-0513","article-title":"Urinary tumor DNA MRD analysis to identify responders to Neoadjuvant immunotherapy in muscle-invasive bladder cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101216_bib0021","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0022","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.neo.2025.101216_bib0023","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2025.101216_bib0024","first-page":"39","article-title":"An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009)","author":"Sheng","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neo.2025.101216_bib0026","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0027","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer (vol 54, 102728, 2020)","volume":"66","author":"Kohli","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neo.2025.101216_bib0028","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.neo.2025.101216_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","article-title":"Cisplatin nephrotoxicity: a review","volume":"334","author":"Yao","year":"2007","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.neo.2025.101216_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0031","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2025.101216_bib0032","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/CCO.0000000000000225","article-title":"Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications","volume":"27","author":"Esposito","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0033","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2025.101216_bib0034","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41585-020-0297-9","article-title":"Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers","volume":"17","author":"Maia","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.neo.2025.101216_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e17113","article-title":"A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Xu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2025.101216_bib0036","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med.-Camb."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558625000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:20:34Z","timestamp":1772889634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558625000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"alternative-id":["S1476558625000958"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2025.101216","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2025.101216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101216"}}